Y-Intercept (HK)’s Keros Therapeutics KROS Stock Holding History

Y-Intercept (HK)’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$515K	Sell	48,176 -116,307	-71%	-$1.3M	0.01%	1307
2026 Q1	$1.82M	Buy	164,483 +47,122	+40%	+$728K	0.03%	762
2025 Q4	$2.39M	Buy	117,361 +68,816	+142%	+$1.21M	0.05%	538
2025 Q3	$768K	Sell	48,545 -56,333	-54%	-$832K	0.02%	1097
2025 Q2	$1.4M	Buy	+104,878	New	+$1.42M	0.03%	775
2025 Q1	–	Sell	-74,255	Closed	-$1.18M	–	1429
2024 Q4	$1.18M	Buy	74,255 +70,561	+1,910%	+$3.67M	0.08%	362
2024 Q3	$215K	Sell	3,694 -34,367	-90%	-$1.7M	0.01%	1135
2024 Q2	$1.74M	Buy	+38,061	New	+$2.05M	0.1%	285
2024 Q1	–	Sell	-5,205	Closed	-$207K	–	1581
2023 Q4	$207K	Buy	+5,205	New	+$163K	0.02%	991

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Y-Intercept (HK)'s KROS Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Keros Therapeutics (KROS) stake by 71% in Q2 2026, selling an estimated $1.3M and leaving 48,176 shares worth $515K. The position accounts for 0.01% of the portfolio, ranked #1307.

Y-Intercept (HK) first reported a position in KROS in Q4 2023 and has held it in 9 quarters since. The position peaked at $2.39M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Y-Intercept (HK) held 48,176 shares of Keros Therapeutics worth $515K as of Q2 2026.
Y-Intercept (HK) sold 116,307 Keros Therapeutics shares in Q2 2026, an estimated $1.3M.
Keros Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1307 holding.
Y-Intercept (HK) first reported a position in Keros Therapeutics in Q4 2023 and has held it in 9 quarters since.
Y-Intercept (HK)'s Keros Therapeutics position peaked at $2.39M in Q4 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.